hrp0095p1-407 | Adrenals and HPA Axis | ESPE2022

Agreement between Acth-low test and Insuline Tolerance Test in Patients with Risk Factors for Central Adrenal Insufficiency

Panciroli Marta , Angelelli Alessia , Fava Daniela , Patti Giuseppa , Napoli Flavia , Di Iorgi Natascia , Maghnie Mohamad

Background: Central adrenal insufficiency(CAI) is a potential life-threatening condition and a prompt diagnosis represents a clinical challenge; indeed, the Insulin Tolerance Test(ITT), gold standard for CAI diagnosis, can be contraindicated in some conditions. Aims were to evaluate the diagnostic value of the ACTH low test(ACTH-LT) compared to the ITT and to identify eventual determinants(primary diagnosis, risk factors, symptoms, baseline cortisol, hypothala...

hrp0097fc8.3 | Fat, metabolism and obesity 2 | ESPE2023

Impact of growth hormone therapy on body mass index in childhood-onset craniopharyngioma: a multicenter Italian study in 117 patients.

Ciacchini Benedetta , Zucchini Stefano , Pozzobon Gabriella , Pedicelli Stefania , Parpagnoli Maria , Driul Daniela , Matarazzo Patrizia , Baronio Federico , Panciroli Marta , Partenope Cristina , Nardini Beatrice , Ubertini Graziamaria , Menardi Rachele , Guzzetti Chiara , Iughetti Lorenzo , Aversa Tommaso , Di Mase Raffaella , Cassio Alessandra , Di Iorgi Natascia

Background: patients with childhood-onset craniopharyngioma (CO-CP) present long-term outcomes, including growth hormone (GH) deficiency and obesity. Currently, data on the effects of GH therapy (GHT) on the body mass index (BMI) in CP are inconclusive. Aims of the study were to evaluate BMI over time and its determinants in a large cohort of CO-CP patients treated with GH therapy (GHT).Methods: a multicenter retrospecti...

hrp0098fc7.4 | GH and IGFs | ESPE2024

Growth Hormone Response to Glucagon Stimulation Test in Transitional Age

Fava Daniela , Vanorio Barbara , Santucci Chiara , Parodi Stefano , Pepe Alessia , Repetto Agnese , Caridi Claudia , Acquarone Lucia , Data Erica , Merlo Silvia , Napoli Flavia , Tedesco Caterina , Angelelli Alessia , Panciroli Marta , Casalini Emilio , Di Iorgi Natascia , Maghnie Mohamad

Context: In the diagnosis of permanent GH deficiency (GHD) during the transition phase, the 2019 AACE guidelines recommended peak GH-cutoffs of ≤3µg/L and ≤1µg/L for the glucagon test (GST), while a recent investigation identified a value <5.8μg/L as a suitable gold standard (Fava et al, Journal of Clinical Endocrinology and Metabolism, 2024). However, the clinical applicability of this cutoff remains to be confirmed and the potential c...